RU2020109345A - Применение мавакамтена для лечения гипертрофической кардиомиопатии - Google Patents

Применение мавакамтена для лечения гипертрофической кардиомиопатии Download PDF

Info

Publication number
RU2020109345A
RU2020109345A RU2020109345A RU2020109345A RU2020109345A RU 2020109345 A RU2020109345 A RU 2020109345A RU 2020109345 A RU2020109345 A RU 2020109345A RU 2020109345 A RU2020109345 A RU 2020109345A RU 2020109345 A RU2020109345 A RU 2020109345A
Authority
RU
Russia
Prior art keywords
compound
daily dose
individual
concentration
specified
Prior art date
Application number
RU2020109345A
Other languages
English (en)
Russian (ru)
Inventor
Марк Дж. СЕМИГРАН
Джун Х. ЛИ
Джозеф ЛЭМБИНГ
Эрик ГРИН
Марк Эванчик
Original Assignee
Миокардиа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Миокардиа, Инк. filed Critical Миокардиа, Инк.
Publication of RU2020109345A publication Critical patent/RU2020109345A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
RU2020109345A 2017-08-04 2018-08-03 Применение мавакамтена для лечения гипертрофической кардиомиопатии RU2020109345A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US62/541,591 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US62/584,537 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US62/639,922 2018-03-07
US201862671585P 2018-05-15 2018-05-15
US62/671,585 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022110225A Division RU2022110225A (ru) 2017-08-04 2018-08-03 Применение мавакамтена для лечения гипертрофической кардиомиопатии

Publications (1)

Publication Number Publication Date
RU2020109345A true RU2020109345A (ru) 2021-09-06

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020109345A RU2020109345A (ru) 2017-08-04 2018-08-03 Применение мавакамтена для лечения гипертрофической кардиомиопатии

Country Status (17)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP3661514B1 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20200035973A (enExample)
CN (2) CN118593507A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG11202000549TA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740481B9 (en) 2018-01-19 2024-10-23 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
US20230158027A1 (en) * 2019-11-10 2023-05-25 MyoKardia, Inc. Methods of treatment with myosin modulator
WO2021154904A1 (en) * 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of mavacamten and process for preparation thereof
EP4203927A4 (en) * 2020-08-28 2024-09-04 MyoKardia, Inc. METHODS OF TREATMENT BY MYOSIN MODULATOR
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
CA3206864A1 (en) * 2021-02-01 2022-08-04 Divya Jyothi Kallem Process for preparation of mavacamten and solid state forms thereof
MX2023010125A (es) 2021-03-04 2023-09-11 Cytokinetics Inc Inhibidores del sarcomero cardiaco.
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
RS66640B1 (sr) * 2021-07-16 2025-04-30 Cytokinetics Inc Režimi doziranja aficamtena za lečenje opstruktivne hipertrofične kardiomiopatije
WO2023046413A1 (en) * 2021-09-24 2023-03-30 Koninklijke Philips N.V. Methods and systems for generating likelihood of heart failure with preserved ejection fraction (hfpef)
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
AU2024248193A1 (en) 2023-03-27 2025-10-09 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Also Published As

Publication number Publication date
MX2024000348A (es) 2024-01-26
MX2020001406A (es) 2020-03-09
CN111182901A (zh) 2020-05-19
KR20250116181A (ko) 2025-07-31
JP2020529996A (ja) 2020-10-15
IL272300B1 (en) 2025-08-01
US20250213565A1 (en) 2025-07-03
AU2024203872A1 (en) 2024-06-27
UY37834A (es) 2019-02-28
EP3661514B1 (en) 2025-09-17
IL322175A (en) 2025-09-01
EP3661514A1 (en) 2020-06-10
US20240423981A1 (en) 2024-12-26
JP2025020292A (ja) 2025-02-12
EP4659806A2 (en) 2025-12-10
MX2024008096A (es) 2024-07-15
CN118593507A (zh) 2024-09-06
CA3071948A1 (en) 2019-02-07
IL272300A (en) 2020-03-31
AU2018311974B2 (en) 2024-03-07
KR20200035973A (ko) 2020-04-06
TW201916882A (zh) 2019-05-01
IL272300B2 (en) 2025-12-01
MY208231A (en) 2025-04-25
SMT202500413T1 (it) 2025-11-10
AU2018311974A1 (en) 2020-02-06
US20200054636A1 (en) 2020-02-20
US20220313695A1 (en) 2022-10-06
WO2019028360A1 (en) 2019-02-07
SG10202112960QA (en) 2021-12-30
US20220226324A1 (en) 2022-07-21
LT3661514T (lt) 2025-11-10
SG11202000549TA (en) 2020-02-27
MA49760A (fr) 2020-06-10
JP2023065372A (ja) 2023-05-12

Similar Documents

Publication Publication Date Title
RU2020109345A (ru) Применение мавакамтена для лечения гипертрофической кардиомиопатии
JP2020529996A5 (enExample)
AU2009252897B2 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
EP2300001A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
Nagaoka et al. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting
CN107296810A (zh) 心舒宁在治疗肥厚型心肌病（hcm）中的应用
Monteagudo et al. Influence of autonomic neuropathy upon left ventricular dysfunction in insulin‐dependent diabetic patients
JPWO2021092598A5 (enExample)
US20250213504A1 (en) Methods of intravenously administering sotalol hydrochloride for the treatment of pediatric patients
US20230225997A1 (en) Methods of administering sotalol hydrochloride
US20240261242A1 (en) Methods of intravenously administering sotalol
TW200946108A (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
RU2022110225A (ru) Применение мавакамтена для лечения гипертрофической кардиомиопатии
Jenkins et al. The symptomatic and objective effects of nifedipine in combination with beta-blocker therapy in severe angina pectoris
JP2011517694A (ja) ドロネダロンと少なくとも１つの利尿薬の組み合わせおよびこの治療的使用
CN119156218A (zh) 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂
Myburgh et al. Comparison of diltiazem and atenolol in young, physically active men with essential hypertension
Bloem et al. Lidoflazine in the management of angina pectoris
RU2255740C2 (ru) Способ подбора дозы дилтиазема для лечения больных постинфарктным кардиосклерозом с недостаточностью кровообращения 2 функционального класса
US20090285893A1 (en) Treatment of heart failure in women
RU2335773C1 (ru) Способ диагностики ранней постинфарктной стенокардии у больных острым инфарктом миокарда
Pomazanov et al. ANTIHYPERTENSIVE THERAPY FOR COMORBID CONDITIONS IN THE PRACTICE OF A FAMILY DOCTOR
Petrella et al. Exercise gas transport determinants in elderly normotensive and hypertensive humans
TW202539641A (zh) 用於治療心臟病之方法
Olsen et al. ACHIEVED SYSTOLIC BLOOD PRESSURE BELOW 130 MMHG PRESERVES KIDNEY FUNCTION IN HIGH-RISK HYPERTENSIVE PATIENTS WITHOUT CARDIAC HYPERTROPHY BUT WITH PROTEINURIA

Legal Events

Date Code Title Description
HC9A Changing information about inventors